Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2002

View Archived Issues

Aventis presents two series of dopamine D3 modulators for schizophrenia and other CNS disorders

Positive phase I results for Prima BioMed's dendritic cell-based therapy

Risperidone positively affects behavioral and psychological symptoms of dementia

Cyclic peptides for use in the treatment of fungal infections and P. carinii pneumonia

Two phase III trials of Xyotax in PS2 NSCLC patients to proceed

New aldose reductase inhibitors in Sankyo development pipeline

Sumitomo researchers identify novel inhibitors of farnesoid X receptor transcription

Provigil study in shift work sleep disorder meets primary endpoints

Novel vitamin D analogues for calcium metabolic disorders covered by Chugai patent

Celltech designs novel alpha4 integrin antagonists

Androgen receptor modulators prepared and tested at Ligand

ALK-Abello and Schering-Plough to develop tablet-based allergy immunotherapy

GeneSoft acquires North American and European rights to Factive from LG Life Sciences

GW-433908 phase III program progresses

Patient randomization completed in phase II liver fibrosis trial of Actimmune

Pharmacopeia and Kowa form antiinflammatory research collaboration

Merck KGaA and Kos establish licensing agreement for Niaspan and Advicor

SBIR grant covers development of pancreatic cancer diagnostic test at Panacea

Antiangiogenic gene therapy enhances radiation-induced tumor vascular destruction

Garenoxacin compares favorably to ofloxacin in terms of chondrotoxicity

Inhibitor of iNOS dimerization shows oral activity in models of rheumatoid arthritis

Improved sensory thresholds reported for milnacipran in rats with spinal nerve injury

Potential use of spironolactone in rheumatoid arthritis

Reduction of serum urate levels reported for febuxostat in gout patients

Suppression of inflammation and joint destruction in RA by oral iNOS inhibitor

IDM and Nemod to develop cancer immunotherapy products

ABT-677 shows comparable efficacy to oseltamivir in mouse models of influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...